Scope, Claims, and US Patent Landscape for Drug US 12,390,430 (Mirdametinib)
What does US 12,390,430 claim, in scope terms?
US 12,390,430 is directed to a specific oral dosing and interruption regimen for mirdametinib in humans, with dose selection based on body surface area (BSA) and with cardiotoxicity-driven withholding and dose reduction keyed to left ventricular ejection fraction (LVEF) changes. The claims are tightly integrated across four dimensions:
- Route and drug form: oral administration of mirdametinib or a pharmaceutically acceptable salt.
- Initial dose schedule: twice daily initiation with BSA-based dose bands.
- Cardiac monitoring and intervention: withholding for asymptomatic absolute LVEF decrease meeting specified magnitude and below LLN, then restarting at a BSA-adjusted reduced dose.
- Protocol operational details: handling of missed doses and emesis; cycle timing (first 21 days of 28-day cycle); assessment cadence (echo schedule); and exposure metrics windows (Cmax, AUC last).
This is a method-of-treatment claim set that reads like an FDA-style regimen: it constrains both when to dose and how to adjust dosing after a defined surrogate endpoint (LVEF decline) and integrates exposure ranges that can be used to define infringement by patient exposure.
What are the claim elements and how they map to enforceable boundaries?
Claim 1 is the independent core regimen
Claim 1 requires all of the following to be present in the administered method:
A. Patient and route
- “A method of administering mirdametinib to a human patient in need thereof”
- “Orally administering mirdametinib or a pharmaceutically acceptable salt thereof”
B. Initial dosing by BSA (twice daily)
- BSA 0.4 to 0.69 m2: 1 mg BID
- BSA 0.7 to 1.04 m2: 2 mg BID
- BSA 1.05 to 1.49 m2: 3 mg BID
- BSA ≥ 1.5 m2: 4 mg BID
C. LVEF-driven withholding and dose reduction
Claim 1 requires the method to further include:
- On exhibiting: asymptomatic absolute decrease in LVEF of 10% or greater from baseline and below LLN
- Withhold “until improvement”
- Restart at a reduced dose, where reduced dosing is again BSA-tiered and twice daily, but lower than initial
Reduced dose specifics:
- BSA 0.4 to 0.69 m2: 1 mg once daily
- BSA 0.7 to 1.04 m2: 2 mg AM + 1 mg PM
- BSA 1.05 to 1.49 m2: 2 mg AM + 2 mg PM
- BSA ≥ 1.5 m2: 3 mg AM + 3 mg PM
D. Implicit timing and “improvement”
Claim 1 does not specify a fixed timeframe for withholding; it relies on a clinical condition (“until improvement”) tied to LVEF recovery.
Dependent claims lock in oncology/indication and regimen mechanics
Dependent claims add narrower contexts and operational features.
Claim 2
- The patient suffers from a tumor or cancer.
Claim 3 (specific tumor/cancer group)
- Cancer is selected from:
- Plexiform neurofibromas (PN)
- PN associated with NF1 (NF1-PN)
- High grade glioma (HGG)
- Low grade ovarian cancer
- Langerhans cell histiocytosis (LCH)
- Brain cancer
- Cancer metastasized to the brain
Claim 4 (tightens the LVEF interval)
- Withholding applies when the decrease is:
- ≥10% and no more than 20% from baseline
- and below LLN
- Restart occurs “until the absolute decrease in LVEF is resolved” at reduced dose.
Claim 5
- Administration with or without food (i.e., food does not avoid the claim).
Claims 6 and 7 (dose omission / vomiting)
- Missed dose: skip and resume at next scheduled dose.
- Vomiting after dose: do not redose; continue next scheduled dose.
Claim 8 (cycle schedule)
- Administer for first 21 days of each 28-day cycle.
Claim 9
- Continue until PN progression or unacceptable toxicity.
Claim 10 (echo cadence)
- Echo by echocardiogram:
- prior to initiation
- every 3 months during the first year
Claims 11 and 12
- Symptomatic PN; progressive PN.
Claim 13-14 (lesion subtypes and anatomic distributions)
- Claim 13 lists compromised airway/great vessels, plexus nerve compression (brachial/lumbar), deformity/disfigurement, extremity hypertrophy/loss of function/painful lesions.
- Claim 14 adds paraspinal lesions.
Claims 15-18 (exposure windows before withholding)
- Claim 15: Cmax about 100 to 500 ng/mL prior to withholding.
- Claim 16: Cmax about 130 to 245 ng/mL prior to withholding.
- Claim 17: AUClast about 200 to 720 ng h/mL prior to withholding.
- Claim 18: AUClast about 250 to 610 ng h/mL prior to withholding.
These exposure claims create an additional infringement hook based on measured pharmacokinetics at steady state “prior to withholding,” tightening proof requirements but widening the evidentiary value when exposure data exists.
How does the claim language define infringement risk for different product implementations?
BSA-based dosing: creates a “recipe” that is hard to design around
Because Claim 1 enumerates initial dosing by BSA ranges and then enumerates reduced dosing by BSA ranges, a competing regimen that changes:
- initial mg per dose,
- twice daily structure,
- BSA thresholds,
- or the reduced-dose split (AM vs PM),
can fall outside literal scope. Conversely, use of the same tiers and schedule creates direct risk.
LVEF threshold and asymptomatic/LLN components: narrows the trigger
The withholding trigger is not simply “LVEF decreases”; it is:
- asymptomatic
- absolute decrease ≥10% from baseline
- below LLN
Then reduction is tied to “improvement” or “resolved” thresholds depending on the claim (Claim 4 adds a magnitude cap of “no more than 20%”).
Operational dosing details: add secondary compliance checkpoints
The missed-dose and vomiting handling rules reduce “intentional divergence” strategies. A clinician could vary these in practice, but if the method in the record matches the claim operational handling, infringement risk increases.
Exposure-window dependent claims: evidence-based enforceability
Claims 15-18 incorporate exposure windows and “prior to withholding.” These are best supported where:
- therapeutic drug monitoring exists or trial PK samples exist,
- and withholding decisions are recorded relative to a steady-state measurement.
The windows do not necessarily avoid infringement if other claim elements are met; they function as additional dependent constraints.
What is the claim set’s practical “distance” from a generic or label alternative?
US 12,390,430 is not limited to a single indication in the independent claim; instead it includes dependent coverage of PN/NF1-PN and multiple oncology contexts. That affects enforcement because litigation can target:
- method-of-use prescribing patterns,
- and clinical trial protocols.
For a product to avoid infringement, it would generally need to diverge in at least one critical dimension:
- initial BSA dosing scheme,
- reduction tiering (including AM/PM split),
- LVEF threshold and “asymptomatic” + LLN criteria,
- or the cycle pattern and dosing behaviors (missed dose/vomiting).
How does the US claim language position “mirdametinib” versus other MEK-pathway competitors?
The enforceable features here are cardiac-safety-labeled titration logic paired with BSA-scaled oral dosing. That combination is distinct from general MEK inhibitor labeling patterns that may use:
- body-weight-based mg/kg rather than BSA bands,
- different cardiotoxicity thresholds,
- different restart rules (e.g., dose hold then fixed reduction step, without AM/PM split),
- or a different monitoring cadence.
A meaningful landscape analysis therefore focuses on whether other assets use:
- the same exact LVEF logic (absolute decrease 10%+, LLN, asymptomatic),
- the same BSA bands (0.4-0.69, 0.7-1.04, 1.05-1.49, ≥1.5),
- and the same reduced-dose mapping.
Patent landscape: what does this imply for US competitive freedom-to-operate?
A tight method claim like this often acts as a secondary barrier even when:
- composition-of-matter protection expires,
- or a later-generation formulation exists.
The “barrier” effect depends on what competing products are doing in actual clinical practice and what their clinical protocols copy.
Key landscape implications (based on claim architecture)
- Clinical protocol copying risk: If a challenger adopts a trial or label regimen with the same BSA bands and LVEF withholding logic, US 12,390,430 becomes difficult to design around.
- In-label use is not required for method infringement: The claim reads as a method; if the medical instructions align, enforcement can target those methods regardless of the origin of the regimen (trial vs routine practice), depending on jurisdictional standards and proof.
- Exposure-based dependent claims raise evidentiary value: PK sampling during development can create records that support meeting Cmax/AUClast limitations “prior to withholding.”
Claim-by-claim scope snapshot (enforceable boundaries)
| Claim |
Adds what constraint |
Main enforceability lever |
| 1 |
BSA-based initial dosing (BID) + LVEF asymptomatic withholding (LVEF decrease ≥10% absolute + below LLN) + reduced dose mapping (including once-daily at lowest band) |
Core dosing recipe and cardiotoxicity algorithm |
| 2 |
Patient has tumor/cancer |
Limits to oncology population (broad) |
| 3 |
Cancer types listed |
Narrows to specific disease contexts |
| 4 |
LVEF decline capped to ≤20% from baseline; withholding until resolution |
Tightens cardiotoxicity window |
| 5 |
With or without food |
Prevents a food-based design-around |
| 6 |
Missed dose rule: skip |
Operational compliance factor |
| 7 |
Vomiting rule: no supplemental dose |
Operational compliance factor |
| 8 |
Cycle: first 21 days each 28-day cycle |
Scheduling structure |
| 9 |
Continue until PN progression/unacceptable toxicity |
Indication-linked endpoint |
| 10 |
Echo: baseline then every 3 months first year |
Monitoring protocol |
| 11 |
Symptomatic PN |
Symptom-state constraint |
| 12 |
Progressive PN |
Disease-state constraint |
| 13 |
Lesion characteristics and anatomic compromise |
Further narrows PN severity patterns |
| 14 |
Paraspinal lesions |
Further lesion type constraint |
| 15 |
Cmax window prior to withholding |
Adds PK-measured constraint |
| 16 |
Narrower Cmax window prior to withholding |
Adds tighter PK constraint |
| 17 |
AUClast window prior to withholding |
Adds PK-measured constraint |
| 18 |
Narrower AUClast window prior to withholding |
Adds tighter PK constraint |
Where are the likely attack and defense points?
- Literal claim construction hotspots
- “asymptomatic” and “below the LLN” drive trigger specificity.
- “absolute decrease” requires baseline comparison and math, not relative change.
- Restart at “reduced dose” requires matching the exact BSA-to-dose mapping (including AM/PM split).
- Proof hotspots in enforcement
- Dosing times (BID vs AM/PM split; reduced dose once daily at lowest BSA band).
- LVEF and LLN determination with baseline.
- Documentation that LVEF decline meets the claim trigger.
- For dependent exposure claims: measured Cmax/AUClast at steady state “prior to withholding.”
Key Takeaways
- US 12,390,430 is a method-of-administration patent with a tightly defined BSA-scaled oral dosing recipe and a cardiotoxicity-driven withholding and dose reduction algorithm based on asymptomatic absolute LVEF decrease ≥10% from baseline and below LLN.
- The reduced-dose mapping is enforceability-critical: it includes once-daily dosing at the lowest BSA tier and specific AM/PM splits at higher tiers.
- Dependent claims expand enforceability through oncology context, specific PN-related lesion severity, protocol operations (missed dose and vomiting), cycle timing, echo cadence, and PK exposure windows for Cmax and AUClast prior to withholding.
- Avoidance requires changing at least one core element (BSA band dosing, LVEF withholding trigger, restart/reduction mapping, or key operational schedule).
FAQs
1) Is US 12,390,430 limited to plexiform neurofibromas (PN)?
No. Claim 1 is not limited by indication, and dependent claims include PN/NF1-PN and also list other cancers in Claim 3.
2) What triggers withholding of mirdametinib under Claim 1?
An asymptomatic absolute LVEF decrease ≥10% from baseline and below the lower limit of normal (LLN).
3) How does the reduced dose differ from the initial dose?
Reduced doses are BSA-tiered and lower than the initial BID dosing; the lowest BSA band becomes 1 mg once daily, while higher bands use AM/PM split reductions.
4) Do the claims allow administration with food?
Yes. Claim 5 states the method is “with or without food.”
5) What additional constraints do Claims 15-18 introduce?
They add PK exposure windows (Cmax and AUClast) measured at steady state and prior to withholding.
References
[1] US Patent 12,390,430. Claims provided in the prompt text.
